Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mechanism by which hydralazine increases propranolol bioavailability.

D W Schneck, J E Vary

    Clinical Pharmacology and Therapeutics
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effect of erythromycin on the pharmacokinetics of rosuvastatin.

    European journal of clinical pharmacology·2003
    Same author

    Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.

    European journal of clinical pharmacology·2003
    Same author

    The effect of fluconazole on the pharmacokinetics of rosuvastatin.

    European journal of clinical pharmacology·2002
    Same author

    Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.

    The Journal of clinical psychiatry·1996
    Same author

    Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.

    Antimicrobial agents and chemotherapy·1995
    Same author

    Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency.

    Journal of clinical pharmacology·1993

    Hydralazine significantly increases propranolol bioavailability by affecting its absorption and distribution, not by altering its metabolic pathways. This drug interaction enhances propranolol

    Area of Science:

    • Pharmacology
    • Drug Metabolism and Pharmacokinetics

    Background:

    • Propranolol is a widely used beta-blocker with variable oral bioavailability.
    • Hydralazine is an antihypertensive agent.
    • Understanding drug interactions is crucial for optimizing therapeutic outcomes.

    Purpose of the Study:

    • To investigate the pharmacokinetic interaction between propranolol and hydralazine.
    • To determine if hydralazine affects propranolol's absorption, metabolism, or excretion.

    Main Methods:

    • Administration of oral 14C-propranolol alone and with varying doses of hydralazine to healthy subjects.
    • Measurement of propranolol concentrations in plasma over time.
    • Analysis of urinary metabolites of 14C-propranolol using High-Performance Liquid Chromatography (HPLC).

    Related Experiment Videos

    Main Results:

    • Hydralazine significantly increased propranolol peak concentrations and the area under the concentration-time curve.
    • Hydralazine reduced the time to reach peak propranolol concentrations.
    • No significant changes were observed in the urinary excretion fraction of propranolol metabolites.

    Conclusions:

    • Hydralazine enhances propranolol bioavailability primarily through hemodynamic effects, not by inhibiting propranolol metabolism.
    • The interaction between hydralazine and propranolol is pharmacokinetic, affecting absorption and distribution.
    • Further research is needed to identify undefined acidic and basic metabolites of propranolol.